Engineering a pure and stable heterodimeric IgA for the development of multispecific therapeutics.
Heinkel, F., Verstraete, M.M., Cao, S., Li, J., Farber, P., Stangle, E., Silva-Moreno, B., Peng, F., Dixit, S., Boulanger, M.J., Spreter Von Kreudenstein, T., Escobar-Cabrera, E.(2022) MAbs 14: 2141637-2141637
- PubMed: 36343329 
- DOI: https://doi.org/10.1080/19420862.2022.2141637
- Primary Citation of Related Structures:  
7TTZ - PubMed Abstract: 
CE-SDS: capillary electrophoresis sodium dodecyl sulfate; DSC: differential scanning calorimetry; FACS: fluorescence-activated cell sorting; FSA: full-sized antibody; Her2: human epidermal growth factor receptor 2; MFI: mean fluorescent intensity; OAA: one-armed antibody; PBS: phosphate-buffered saline; PDB: Protein Data Bank; SEC: size-exclusion chromatography; prepSEC (preparative SEC); RMSD: root-mean-square deviation; RU: resonance units; SPR: surface plasmon resonance; TAA: tumor-associated antigen; WT: wild-type.
Organizational Affiliation: 
Zymeworks Inc., Vancouver, BC, Canada.